BD to Present at Barclays 28th Annual Global Healthcare Conference
PRNewswire (Mon, 23-Feb 4:15 PM ET)
BD Expands Testing Capabilities to Help Clinicians Improve Diagnostic Accuracy and Efficiency
PRNewswire (Mon, 23-Feb 6:50 AM ET)
Lanesha Minnix Named General Counsel for BD
PRNewswire (Thu, 19-Feb 4:15 PM ET)
Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
PRNewswire (Tue, 10-Feb 1:00 PM ET)
Waters Completes Combination with BD's Biosciences & Diagnostic Solutions Businesses
PRNewswire (Mon, 9-Feb 8:40 AM ET)
BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation
PRNewswire (Mon, 9-Feb 8:40 AM ET)
BD's Strategic Shift and Segment Performance Drive Solid Start to Fiscal 2026
Market Chameleon (Mon, 9-Feb 2:32 AM ET)
BD Reports First Quarter Fiscal 2026 Financial Results
PRNewswire (Mon, 9-Feb 6:30 AM ET)
BD and Envetec Demonstrate Closed-Loop Recycling Solution for Laboratory Plastics in Health Care
PRNewswire (Thu, 29-Jan 6:50 AM ET)
PRNewswire (Tue, 27-Jan 4:15 PM ET)
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.
Becton Dickinson And Company trades on the NYSE stock market under the symbol BDX.
As of February 24, 2026, BDX stock price declined to $182.49 with 2,721,594 million shares trading.
BDX has a beta of 0.46, meaning it tends to be less sensitive to market movements. BDX has a correlation of 0.06 to the broad based SPY ETF.
BDX has a market cap of $51.91 billion. This is considered a Large Cap stock.
Last quarter Becton Dickinson And Company reported $5 billion in Revenue and $2.91 earnings per share. This beat revenue expectation by $104 million and exceeded earnings estimates by $.09.
In the last 3 years, BDX traded as high as $287.32 and as low as $162.29.
The top ETF exchange traded funds that BDX belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
BDX has underperformed the market in the last year with a return of +1.6%, while SPY returned +15.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BDX shares. However, BDX has outperformed the market in the last 3 month and 2 week periods, returning +18.3% and +39.2%, while SPY returned +4.6% and -1.0%, respectively. This indicates BDX has been having a stronger performance recently.
BDX support price is $180.96 and resistance is $187.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDX shares will trade within this expected range on the day.